Allogene Therapeutics Announces Participation in February Investor Conferences

Posted: February 5, 2025 at 2:42 am

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in February.

Continued here:
Allogene Therapeutics Announces Participation in February Investor Conferences

Related Posts